A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.
AffiliationChristie Hospital, Manchester, M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractAngiogenesis plays an important role in the formation of new blood vessels and is crucial for tumour development and progression. Imbalance between pro- and antiangiogenesis factors regulates the biological process of angiogenesis. The best characterised of the proangiogenic factors and the most potent is vascular endothelial growth factor (VEGF). The binding of VEGF to one of its transmembrane tyrosine kinase receptors, which are predominantly found on endothelial cells, results in receptor dimerisation, activation and autophosphorylation of the tyrosine kinase domain. This triggers a cascade of complex downstream signalling pathways. Several strategies targeting the VEGF signalling pathway have been developed. These include neutralising antibodies to VEGF (bevacizumab) or VEGF receptors (VEGFRs) (DC101), soluble VEGFR/VEGFR hybrids (VEGF-Trap), and tyrosine kinase inhibitors of VEGFRs (BAY43-9006, SU11248, ZD6474, AZD2171, PTK/ZK and others). Several of these agents are now being investigated in clinical trials.
CitationA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006, 10 (6):867-76 Expert Opin. Ther. Targets
JournalExpert Opinion on Therapeutic Targets
- Vascular endothelial growth factor (VEGF) inhibition by small molecules.
- Authors: Ahmed SI, Thomas AL, Steward WP
- Issue date: 2004 Nov
- Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
- Authors: Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D
- Issue date: 2006
- VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
- Authors: Sharma PS, Sharma R, Tyagi T
- Issue date: 2011 Jun
- The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
- Authors: Tarallo V, De Falco S
- Issue date: 2015 Jul
- Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
- Authors: Wood JM
- Issue date: 2000